In its filing, Isis said it would have 111.7 million shares of common stock outstanding when the offering closes...Isis has 28 candidates in preclinical and clinical development across a wide variety of indications, with nine scheduled to report data in the next 12 months

AG014 comprises oral delivery of an anti-TNF antibody with proven clinical efficacy in IBD, resulting in local efficacy and an improved safety profile over systemic drugs...That's the sweet spot for a number of pharma companies...ERYtech Pharma SA, of Lyon, France, has had its prospectus accepted for a proposed initial public offering on the NYSE Euronext exchange in Paris

Coronado Biosciences Inc., of Burlington, Mass., sold 1 million shares of common stock through its at-the-market program to Jennison Associates LLC, on behalf of fund clients, at Wednesday's closing price of $10...Coronado plans to use the proceeds to fund R&D, clinical trials and manufacture of supply as well as other corporate purposes

MEI Pharma Inc., of San Diego, priced a public offering of about 2 million shares of common stock at $7.50 apiece, a 9.5 percent discount to Thursday's closing price

A big pharma partner could ease some of the pressure on Vivus...They purchased 470,000 shares of common stock at $5.24 per share and 840,000 Series 2013-A warrants at $0.01 per warrant, which are good for 420,000 shares at $6.78, exercisable until Feb. 13, 2018...The funds will be used to advance Theraclone's clinical programs and support its I-STAR technology platform.

upsized a public offering of about 2.9 million shares of common stock, priced at $20.75, seeking to raise $59.7 million...Hyperion gained rights to Ravicti from Ucyclyd Pharma Inc., a subsidiary of Scottsdale, Ariz.-based Medicis Pharmaceutical Corp...at the same unit price.

Dezima Pharma BV, of Naarden, the Netherlands, said it raised €14.2 million (US$18.6 million) for the clinical development of its cholesteryl ester transfer protein (CETP) inhibitor, DEZ-001 (previously TA-8995), and to develop additional earlier-stage dyslipidemia assets...It will use the proceeds to advance its opthalmic programs through clinical proof of concept

As this money is dispensed through its clinical development programs, the company expects to receive £12 million in government R&D tax credits, bringing the total pot to £60 million...Pharma doesn't want more questions than answers, so you can't do development on a shoestring or cut corners...The total amount raised in the private placement is $7.9 million.

New York investment fund Platinum-Montaur Life Sciences LLC exercised Series W warrants to purchase 6 million shares of common stock in Navidea Biopharmaceuticals Inc., of Dublin, Ohio

Arno is conducting clinical and preclinical studies of three drug candidates to treat a variety of cancers...MEI Pharma Inc., of San Diego, completed a private placement of common stock and warrants in a financing led by new investors Vivo Ventures and New Leaf Venture Partners...NeRRe Therapeutics Ltd., of London, raised £11.5 million (US$18.4 million) to develop a portfolio of clinical and preclinical neurokinin receptor antagonists divested from GlaxoSmithKline plc, also of London. #kicker123

Infinity also issued 1.9 million shares of common stock to Purdue Pharma LP, generating proceeds of $27.5 million and giving Purdue a 28 percent stake in the company...The company plans to use the proceeds to fund research and development, clinical trials and for other corporate purposes.

At least a year shy of the next milestone payment from partner Astellas Pharma Inc., Ambit Biosciences Inc...Funds will be used for working capital and general corporate purposes, including the funding of its ongoing clinical trials...The net proceeds will be used for working capital and general corporate purposes, including the continued conduct of the Abili-T clinical study, Opexa's recently initiated Phase IIb trial of personalized T-cell therapy Tcelna in patients with secondary progressive

Shares of MEI Pharma Inc. (NASDAQ:MEIP) popped on Monday morning and climbed throughout the day after the company disclosed a $27.5 million private placement...The company laid groundwork for clinical trials in advance of the financing and plans to begin a "very substantial" randomized Phase II study in the U.S...The company also received $25.0 million from the sale of common stock in a private placement to strategic partner AstraZeneca plc, of London, that closed concurrently with the IPO, and $5.0

About a year earlier, Dutch firm AM-Pharma BV banked €29.2 million (then US$39.8 million) in a Series D round, apparently the largest venture capital financing in Dutch biotechnology thus far...The company planned to switch from a bovine to a recombinant form of its AKI treatment, alkaline phosphatase. (See BioWorld Today, Sept. 14, 2011.) Bunnik, the Netherlands-based AM-Pharma had then gained only preliminary data from two small-scale clinical trials suggesting that bovine alkaline phosphatase

Noting a trend for pharma companies to engage in more collaborations and acquisitions in order to supplement their pipelines with new technology, Lammers said he could envision such an outcome for Mirna...Given the interest of big pharma in microRNA companies, including Mirna, I'm convinced if we have strong human proof-of-concept data in the clinic, most likely pharma will be interested in stepping up to the plate," Lammers said

The clinical relevance of neratinib as a 'pan-HER' family inhibitor and it being irreversible is yet to be proven," the paper said...Each unit consists of one share of common stock and one warrant to purchase a half share of common stock...Funds will be used to support the clinical development of cancer drugs aldoxorubicin and tamibarotene and for general corporate purposes, which could include working capital, capital expenditures, R&D and commercial activities.

Proceeds will be used to fund ACT's clinical activities, including its three ongoing Phase I/II trials for forms of macular degeneration, for development of its other clinical activities and for general corporate purposes...Horizon Pharma Inc., of Deerfield, Ill., priced an underwritten public offering of 21.42 million units, with each unit consisting of one share of its common stock and a warrant to purchase a half share of its common stock...Royalty Pharma has invested $25 million under its royalty

The Haifa, Israel-based biotech is selling 8 million units – each comprising one share of common stock and one warrant to purchase 0.35 of a share – priced Thursday at $4 apiece...Pluristem's platform already has captured the attention of pharma...Proceeds will be used to support clinical studies, R&D activities and for general corporate purposes, including working capital and administrative expenses

Vascular Pharma will receive an up-front payment and milestone payments in exchange for the acquisition rights...Vascular Pharma expects its funding to last through completion of Phase II, getting the company to the point where Janssen may exercise its option...Pharma giants Boehringer Ingelheim GmbH, of Ingelheim, Germany, and Eli Lilly and Co., of Indianapolis, have thrown their hats into the ring, as well